The road to success of coagulase-negative staphylococci: clinical significance of small colony variants and their pathogenic role in persistent infections.

CoNS pathogenesis Coagulase-negative staphylococci Device-related infections Intracellular persistence Small colony variants Staphylococcus epidermidis

Journal

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
ISSN: 1435-4373
Titre abrégé: Eur J Clin Microbiol Infect Dis
Pays: Germany
ID NLM: 8804297

Informations de publication

Date de publication:
Nov 2021
Historique:
received: 23 05 2021
accepted: 09 07 2021
pubmed: 24 7 2021
medline: 24 12 2021
entrez: 23 7 2021
Statut: ppublish

Résumé

Bacterial small colony variants represent an important aspect of bacterial variability. They are naturally occurring microbial subpopulations with distinctive phenotypic and pathogenic traits, reported for many clinically important bacteria. In clinical terms, SCVs tend to be associated with persistence in host cells and tissues and are less susceptible to antibiotics than their wild-type (WT) counterparts. The increased tendency of SCVs to reside intracellularly where they are protected against the host immune responses and antimicrobial drugs is one of the crucial aspects linking SCVs to recurrent or chronic infections, which are difficult to treat. An important aspect of the SCV ability to persist in the host is the quiescent metabolic state, reduced immune response and expression a changed pattern of virulence factors, including a reduced expression of exotoxins and an increased expression of adhesins facilitating host cell uptake. The purpose of this review is to describe in greater detail the currently available data regarding CoNS SCV and, in particular, their clinical significance and possible mechanisms by which SCVs contribute to the pathogenesis of the chronic infections. It should be emphasized that in spite of an increasing clinical significance of this group of staphylococci, the number of studies unraveling the mechanisms of CoNS SCVs formation and their impact on the course of the infectious process is still scarce, lagging behind the studies on S. aureus SCVs.

Identifiants

pubmed: 34296355
doi: 10.1007/s10096-021-04315-1
pii: 10.1007/s10096-021-04315-1
pmc: PMC8520507
doi:

Substances chimiques

Bacterial Proteins 0
Coagulase 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

2249-2270

Informations de copyright

© 2021. The Author(s).

Références

PLoS One. 2009;4(4):e5210
pubmed: 19381294
PLoS One. 2013 May 21;8(5):e65018
pubmed: 23705029
Cell Microbiol. 2016 Jan;18(1):80-96
pubmed: 26248337
PLoS Pathog. 2012;8(3):e1002551
pubmed: 22457616
J Clin Microbiol. 1990 Apr;28(4):676-9
pubmed: 2332465
J Med Microbiol. 2014 Feb;63(Pt 2):176-185
pubmed: 24257683
Braz J Microbiol. 2020 Jun;51(2):601-612
pubmed: 31828715
J Bacteriol. 1997 Aug;179(15):4706-12
pubmed: 9244256
Front Immunol. 2017 Oct 24;8:1368
pubmed: 29114249
Front Cell Infect Microbiol. 2014 Jul 28;4:99
pubmed: 25120957
Clin Microbiol Infect. 2019 Sep;25(9):1071-1080
pubmed: 30502487
J Microbiol. 2015 Aug;53(8):544-52
pubmed: 26224457
Sci Rep. 2017 Jul 6;7(1):4811
pubmed: 28684793
Clin Microbiol Rev. 2016 Apr;29(2):401-27
pubmed: 26960941
Antimicrob Agents Chemother. 2008 Jun;52(6):2183-9
pubmed: 18378706
Diagn Microbiol Infect Dis. 2012 Nov;74(3):224-9
pubmed: 22901790
Infect Immun. 2011 Nov;79(11):4569-77
pubmed: 21844240
J Infect Dis. 2010 Oct 1;202(7):1031-40
pubmed: 20715929
Infect Immun. 2005 Jul;73(7):4119-26
pubmed: 15972501
Med Mal Infect. 2017 Nov;47(7):498-501
pubmed: 28943172
Infect Immun. 2002 Oct;70(10):5428-37
pubmed: 12228267
J Infect Dis. 2017 Feb 1;215(3):488-490
pubmed: 27974434
Infect Immun. 2014 Apr;82(4):1600-5
pubmed: 24452687
J Antimicrob Chemother. 2013 Jul;68(7):1455-64
pubmed: 23485724
Antimicrob Agents Chemother. 2008 Apr;52(4):1533-7
pubmed: 18285476
Emerg Infect Dis. 2005 Aug;11(8):1283-6
pubmed: 16102320
Injury. 2006 May;37 Suppl 2:S26-33
pubmed: 16651068
mBio. 2014 Jul 29;5(4):e01447-14
pubmed: 25073642
N Engl J Med. 2007 Aug 16;357(7):654-63
pubmed: 17699815
PLoS Pathog. 2015 Apr 29;11(4):e1004870
pubmed: 25923704
PLoS One. 2013 Oct 18;8(10):e77614
pubmed: 24204894
Int J Med Microbiol. 2020 Dec;310(8):151463
pubmed: 33197865
J Infect Dis. 1998 Apr;177(4):1023-9
pubmed: 9534977
Immunol Invest. 2018 Apr;47(3):251-263
pubmed: 29336620
Microb Drug Resist. 2002 Winter;8(4):253-60
pubmed: 12523621
Microbiol Insights. 2015 Sep 22;8:15-23
pubmed: 26448688
J Bacteriol. 2006 Jan;188(1):64-76
pubmed: 16352822
Cytokine. 2002 Aug 21;19(4):206-12
pubmed: 12297115
Infect Immun. 2018 Sep 21;86(10):
pubmed: 30061380
Infect Immun. 2015 Feb;83(2):470-81
pubmed: 25385795
J Infect Dis. 2000 Apr;181(4):1337-49
pubmed: 10762565
J Infect Dis. 1996 Mar;173(3):739-42
pubmed: 8627043
Int J Med Microbiol. 2010 Feb;300(2-3):170-5
pubmed: 19781990
J Antimicrob Chemother. 2007 May;59(5):848-53
pubmed: 17337510
BMC Res Notes. 2015 Dec 08;8:749
pubmed: 26643526
Pathogens. 2021 Feb 04;10(2):
pubmed: 33557202
Microb Pathog. 2010 Jan;48(1):18-27
pubmed: 19825410
J Bacteriol. 2008 Feb;190(3):834-42
pubmed: 17905979
Cell Host Microbe. 2018 May 9;23(5):594-606.e7
pubmed: 29706505
Int J Med Microbiol. 2003 Dec;293(6):427-35
pubmed: 14760974
Front Cell Infect Microbiol. 2012 Apr 24;2:43
pubmed: 22919634
Front Cell Infect Microbiol. 2014 Oct 21;4:141
pubmed: 25374845
J Bacteriol. 2007 Jun;189(12):4494-501
pubmed: 17449620
mBio. 2014 Sep 30;5(5):e01910-14
pubmed: 25271290
J Infect Dis. 2003 May 15;187(10):1654-61
pubmed: 12721946
Virology. 2015 May;479-480:568-77
pubmed: 25798530
PLoS Pathog. 2010 Jun 10;6(6):e1000944
pubmed: 20548948
J Clin Microbiol. 2010 Aug;48(8):2878-84
pubmed: 20554819
J Appl Microbiol. 2020 Nov;129(5):1102-1119
pubmed: 32416020
Front Microbiol. 2015 Oct 27;6:1174
pubmed: 26579084
J Bacteriol. 2003 Dec;185(23):6928-37
pubmed: 14617657
Antimicrob Agents Chemother. 2007 Dec;51(12):4255-60
pubmed: 17923487
N Engl J Med. 2012 Jun 14;366(24):2267-75
pubmed: 22693998
J Bacteriol. 2012 Oct;194(19):5404-12
pubmed: 22865841
Curr Opin Infect Dis. 2000 Jun;13(3):233-240
pubmed: 11964792
J Antimicrob Chemother. 2011 Dec;66(12):2809-13
pubmed: 21948963
Antimicrob Agents Chemother. 2009 Sep;53(9):3992-5
pubmed: 19564372
PLoS One. 2011;6(11):e28366
pubmed: 22140579
PLoS Pathog. 2010 Oct 07;6(10):e1001133
pubmed: 20949069
Clin Infect Dis. 1998 Aug;27 Suppl 1:S68-74
pubmed: 9710673
Front Microbiol. 2020 May 21;11:1028
pubmed: 32508801
J Infect Dis. 2016 Jan 15;213(2):305-13
pubmed: 26188074
J Bacteriol. 2006 Nov;188(22):7765-77
pubmed: 16980462
EMBO Mol Med. 2011 Mar;3(3):115-7
pubmed: 21365763
Nat Rev Microbiol. 2006 Apr;4(4):295-305
pubmed: 16541137
PLoS One. 2011;6(9):e24827
pubmed: 21931858
Front Microbiol. 2017 Aug 02;8:1401
pubmed: 28824556
EMBO Mol Med. 2011 Mar;3(3):129-41
pubmed: 21268281
Clin Infect Dis. 1997 Nov;25(5):1250-1
pubmed: 9402396
PLoS One. 2018 Nov 9;13(11):e0207312
pubmed: 30412620
J Bacteriol. 2008 Oct;190(19):6351-64
pubmed: 18676673
BMC Microbiol. 2010 Jan 30;10:33
pubmed: 20113519
Clin Infect Dis. 1999 Oct;29(4):932-4
pubmed: 10589914
PLoS One. 2012;7(5):e36602
pubmed: 22586482
Eur J Clin Microbiol Infect Dis. 2003 Dec;22(12):746-8
pubmed: 14605939
Microbes Infect. 2015 Mar;17(3):173-83
pubmed: 25637951
Front Microbiol. 2020 Feb 28;11:321
pubmed: 32184775
Trends Microbiol. 2009 Feb;17(2):54-8
pubmed: 19162480
Antimicrob Agents Chemother. 2007 Dec;51(12):4438-46
pubmed: 17923494
Mol Microbiol. 2008 Dec;70(6):1540-55
pubmed: 19007412
Int J Med Microbiol. 2007 Jul;297(4):217-25
pubmed: 17412637
PLoS Pathog. 2021 Feb 5;17(2):e1009304
pubmed: 33544760
J Infect Dis. 1994 Oct;170(4):1033-7
pubmed: 7930701
Infect Genet Evol. 2014 Jan;21:515-22
pubmed: 23722021
Proteomics. 2011 Jun;11(12):2476-90
pubmed: 21595038
Clin Microbiol Infect. 2016 Sep;22(9):799-809
pubmed: 27393124
J Antimicrob Chemother. 2005 Dec;56(6):1126-9
pubmed: 16287983
Microorganisms. 2021 Apr 14;9(4):
pubmed: 33919781
Microbes Infect. 2007 Apr;9(4):460-5
pubmed: 17331787
PLoS One. 2008 Jan 09;3(1):e1409
pubmed: 18183290
Front Microbiol. 2018 Aug 14;9:1863
pubmed: 30154773
J Bacteriol. 2007 Apr;189(7):2936-40
pubmed: 17259321
Virulence. 2017 Nov 17;8(8):1761-1775
pubmed: 28762868
Cell Microbiol. 2010 Dec;12(12):1746-64
pubmed: 20642807
Front Cell Infect Microbiol. 2016 Dec 26;6:187
pubmed: 28083514
Arthroplast Today. 2018 Jul 30;4(3):257-260
pubmed: 30186900
J Bacteriol. 2006 Jan;188(2):687-93
pubmed: 16385058
PLoS One. 2013 Jun 28;8(6):e67240
pubmed: 23840636
J Clin Microbiol. 2003 Sep;41(9):4424-7
pubmed: 12958283

Auteurs

Agnieszka Bogut (A)

Chair and Department of Medical Microbiology, Medical University of Lublin, ul. Chodźki 1, 20-093, Lublin, Poland.

Agnieszka Magryś (A)

Chair and Department of Medical Microbiology, Medical University of Lublin, ul. Chodźki 1, 20-093, Lublin, Poland. agnieszka.magrys@umlub.pl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH